Fluciclovine (18F) PET/CT scan led to change in treatment plan for 61 percent of patients: Blue Earth Diagnostics

Press releases may be edited for formatting or style | September 26, 2017 Molecular Imaging PET

About Blue Earth Diagnostics
Blue Earth Diagnostics is a molecular imaging diagnostics company focused on the development and commercialization of novel PET imaging agents to inform clinical management and guide care for cancer patients in areas of unmet medical need. Formed in 2014, Blue Earth Diagnostics is led by recognized experts in the clinical development and commercialization of innovative nuclear medicine products. The company's first approved and commercially available product is Axumin® (fluciclovine F 18), a novel molecular imaging agent approved in the United States and European Union for use in PET imaging to detect and localize prostate cancer in men experiencing suspected biochemical recurrence. Blue Earth Diagnostics is backed by Syncona, an investment company listed on the London Stock Exchange (LON: SYNC). For more information, visit: www.blueearthdiagnostics.com.

Back to HCB News

Training and education based on your needs

Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money



You Must Be Logged In To Post A Comment Sign In If you've already created an account, use your email address and password to sign in using the form below. Login Problems: Click here if you are having login issues. Email address: Password: Forgot your password? Login Problems? View our Legal Notice and Privacy Notice Register Registration is Free and Easy. Enjoy the benefits of The World's Leading New & Used Medical Equipment Marketplace. Register Now!